This trial is unknown!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Smoking Cessation or Tobacco Dependence
and you are
between 18 and 65
years old
Phase
4
The primary goal of this phase is to monitor the long-term effects.
The treatment is already on the market.
Show me locations

The purpose

As an add-on treatment to behavioural therapy for tobacco dependence, anodal transcranial direct current stimulation (tDCS) significantly increases the cessation rate compared to treatment with sham tDCS; endpoint analysis will be performed 1, 3, 6 and 12 months after completion of the smoke-free programme in combination with tDCS. Craving, assessed with a visual analog scale (VAS), is reduced significantly in the verum treatment group compared to the sham tDCS group. tDCS is suitable for use in larger groups (8-12 people).

Provided treatments

  • Other: tDCS
  • Behavioral: standardised behavioural therapy
Tris trial is registered with FDA with number: NCT01729507. The sponsor of the trial is Ludwig-Maximilians - University of Munich and it is looking for 40 volunteers for the current phase.
Official trial title:
Transcranial Direct Current Stimulation (TDCS) as Add on Therapy for Treatment of Tobacco Dependence by Standardized Behaviour Therapy - Active and Placebo Controlled Double Blind Study